Evaluation of US20150011555. An inhaled IP receptor agonist for the treatment of pulmonary arterial hypertension
{{output}}
Introduction: Pulmonary arterial hypertension (PAH) is a rare disease for which IP receptor agonists provide one of the main classes of treatment. Currently available agents tend to lack receptor selectivity. ... ...
